-
1
-
-
79958748633
-
A systematic review of hepatitis C virus epidemiology in Europe Canada and Israel
-
PID: 21651702
-
Cornberg, M., Razavi, H.A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C., Dalgard, O., Dillion, J.F., Flisiak, R., Forns, X., et al.: A systematic review of hepatitis C virus epidemiology in Europe Canada and Israel. Liver Int. 31(Suppl 2), 30–60 (2011)
-
(2011)
Liver Int.
, vol.31
, pp. 30-60
-
-
Cornberg, M.1
Razavi, H.A.2
Alberti, A.3
Bernasconi, E.4
Buti, M.5
Cooper, C.6
Dalgard, O.7
Dillion, J.F.8
Flisiak, R.9
Forns, X.10
-
2
-
-
84947502296
-
-
Management of Hepatitis C: (2002)
-
Management of Hepatitis C: (2002). http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
-
-
-
-
3
-
-
84869988183
-
The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States
-
COI: 1:STN:280:DC%2BC2c%2FlvVWhsg%3D%3D, PID: 23177279
-
Ward, J.W.: The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin. Liver Dis. 17, 1–11 (2013)
-
(2013)
Clin. Liver Dis.
, vol.17
, pp. 1-11
-
-
Ward, J.W.1
-
4
-
-
84947502297
-
-
Hepatitis C FAQs for the Public
-
Hepatitis C FAQs for the Public. http://www.cdc.gov/hepatitis/C/cFAQ.htm
-
-
-
-
5
-
-
0029894579
-
The natural history of chronic hepatitis C infection
-
COI: 1:STN:280:DyaK28znsFGrtQ%3D%3D, PID: 8781898
-
Strader, D.B., Seeff, L.B.: The natural history of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol. 8, 324–328 (1996)
-
(1996)
Eur. J. Gastroenterol. Hepatol.
, vol.8
, pp. 324-328
-
-
Strader, D.B.1
Seeff, L.B.2
-
6
-
-
74549128529
-
Epidemiology of hepatitis B and C viruses: a global overview
-
PID: 20123436
-
Te, H.S., Jensen, D.M.: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14, 1–21, vii (2010)
-
(2010)
Clin Liver Dis
, vol.14
, pp. 1-21
-
-
Te, H.S.1
Jensen, D.M.2
-
7
-
-
84857683435
-
Current status and future directions in the management of chronic hepatitis C
-
PID: 22385500
-
Aman, W., Mousa, S., Shiha, G., Mousa, S.A.: Current status and future directions in the management of chronic hepatitis C. Virol. J 9, 57 (2012)
-
(2012)
Virol. J
, vol.9
, pp. 57
-
-
Aman, W.1
Mousa, S.2
Shiha, G.3
Mousa, S.A.4
-
8
-
-
0030928695
-
Hepatitis C: the clinical spectrum of disease
-
COI: 1:STN:280:DyaK2svkvFWruw%3D%3D, PID: 9305658
-
Hoofnagle, J.H.: Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S–20S (1997)
-
(1997)
Hepatology
, vol.26
, pp. 15-20
-
-
Hoofnagle, J.H.1
-
9
-
-
0034802218
-
Estimating progression to cirrhosis in chronic hepatitis C virus infection
-
COI: 1:STN:280:DC%2BD3Mrjs1WisQ%3D%3D, PID: 11584380
-
Freeman, A.J., Dore, G.J., Law, M.G., Thorpe, M., Von Overbeck, J., Lloyd, A.R., Marinos, G., Kaldor, J.M.: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34, 809–816 (2001)
-
(2001)
Hepatology
, vol.34
, pp. 809-816
-
-
Freeman, A.J.1
Dore, G.J.2
Law, M.G.3
Thorpe, M.4
Von Overbeck, J.5
Lloyd, A.R.6
Marinos, G.7
Kaldor, J.M.8
-
11
-
-
79952459766
-
Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006
-
COI: 1:STN:280:DC%2BC3M7ksFOluw%3D%3D, PID: 20587118
-
McDonald, S.A., Hutchinson, S.J., Bird, S.M., Mills, P.R., Hayes, P., Dillon, J.F., Goldberg, D.J.: Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006. Epidemiol. Infect. 139, 344–353 (2011)
-
(2011)
Epidemiol. Infect.
, vol.139
, pp. 344-353
-
-
McDonald, S.A.1
Hutchinson, S.J.2
Bird, S.M.3
Mills, P.R.4
Hayes, P.5
Dillon, J.F.6
Goldberg, D.J.7
-
12
-
-
77955481506
-
Hepatitis C virus infection and risk of cancer: a population-based cohort study
-
PID: 20865115
-
Omland, L.H., Farkas, D.K., Jepsen, P., Obel, N., Pedersen, L.: Hepatitis C virus infection and risk of cancer: a population-based cohort study. Clin. Epidemiol. 2, 179–186 (2010)
-
(2010)
Clin. Epidemiol.
, vol.2
, pp. 179-186
-
-
Omland, L.H.1
Farkas, D.K.2
Jepsen, P.3
Obel, N.4
Pedersen, L.5
-
14
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: an update
-
COI: 1:CAS:528:DC%2BD1MXkslWjs7o%3D, PID: 19330875
-
Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B., American Association for the Study of Liver D: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009)
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
American Association for the Study of Liver, D.5
-
15
-
-
84993709368
-
New agents for the treatment of hepatitis C in patients co-infected with HIV
-
PID: 25165545
-
Munteanu, D.I., Rockstroh, J.K.: New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther. Adv. Infect. Dis. 1, 71–80 (2013)
-
(2013)
Ther. Adv. Infect. Dis.
, vol.1
, pp. 71-80
-
-
Munteanu, D.I.1
Rockstroh, J.K.2
-
16
-
-
84873580144
-
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials
-
COI: 1:CAS:528:DC%2BC3sXhs1entLg%3D, PID: 23369368
-
Sitole, M., Silva, M., Spooner, L., Comee, M.K., Malloy, M.: Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin. Ther. 35, 190–197 (2013)
-
(2013)
Clin. Ther.
, vol.35
, pp. 190-197
-
-
Sitole, M.1
Silva, M.2
Spooner, L.3
Comee, M.K.4
Malloy, M.5
-
17
-
-
84879141644
-
Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review
-
PID: 23556044
-
Bota, S., Sporea, I., Sirli, R., Popescu, A., Neghina, A.M., Danila, M., Strain, M.: Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J. Hepatol. 5, 120–126 (2013)
-
(2013)
World J. Hepatol.
, vol.5
, pp. 120-126
-
-
Bota, S.1
Sporea, I.2
Sirli, R.3
Popescu, A.4
Neghina, A.M.5
Danila, M.6
Strain, M.7
-
18
-
-
84874596467
-
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes
-
PID: 23420134
-
Manos, M.M., Ho, C.K., Murphy, R.C., Shvachko, V.A.: Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient 6, 23–34 (2013)
-
(2013)
Patient
, vol.6
, pp. 23-34
-
-
Manos, M.M.1
Ho, C.K.2
Murphy, R.C.3
Shvachko, V.A.4
-
19
-
-
84874101281
-
Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review
-
PID: 23550100
-
Modabbernia, A., Poustchi, H., Malekzadeh, R.: Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat. Mon. 13, e8340 (2013)
-
(2013)
Hepat. Mon.
, vol.13
, pp. 8340
-
-
Modabbernia, A.1
Poustchi, H.2
Malekzadeh, R.3
-
20
-
-
84862738738
-
Management of side-effects
-
PID: 22248698
-
Rosa, I.: Management of side-effects. Clin. Res. Hepatol. Gastroenterol. 35(Suppl 2), S69–S74 (2011)
-
(2011)
Clin. Res. Hepatol. Gastroenterol.
, vol.35
, pp. 69-74
-
-
Rosa, I.1
-
21
-
-
77954746102
-
Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry
-
COI: 1:CAS:528:DC%2BC3cXhtV2nt7zJ, PID: 20500732
-
Alam, I., Stainbrook, T., Cecil, B., Kistler, K.D.: Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment. Pharmacol. Ther. 32, 535–542 (2010)
-
(2010)
Aliment. Pharmacol. Ther.
, vol.32
, pp. 535-542
-
-
Alam, I.1
Stainbrook, T.2
Cecil, B.3
Kistler, K.D.4
-
22
-
-
79960964116
-
Patient preferences and assessment of likely adherence to hepatitis C virus treatment
-
COI: 1:STN:280:DC%2BC3MjhsFCnug%3D%3D, PID: 20579276
-
Brett Hauber, A., Mohamed, A.F., Beam, C., Medjedovic, J., Mauskopf, J.: Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J. Viral Hepat. 18, 619–627 (2011)
-
(2011)
J. Viral Hepat.
, vol.18
, pp. 619-627
-
-
Brett Hauber, A.1
Mohamed, A.F.2
Beam, C.3
Medjedovic, J.4
Mauskopf, J.5
-
23
-
-
84881239177
-
Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran
-
PID: 24032043
-
Ravi, S., Nasiri Toosi, M., Karimzadeh, I., Ahadi-Barzoki, M., Khalili, H.: Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran. Hepat. Mon. 13, e11038 (2013)
-
(2013)
Hepat. Mon.
, vol.13
, pp. 11038
-
-
Ravi, S.1
Nasiri Toosi, M.2
Karimzadeh, I.3
Ahadi-Barzoki, M.4
Khalili, H.5
-
24
-
-
84947487813
-
-
Agency for Healthcare Research and Quality, December
-
Sun, X., Patnode, C., Williams, C., Senger, C., Kapka, T., Whitlock, E.: Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness. Comparative effectiveness review no. 91. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 13-EHC009-EF. Rockville, MD: Agency for Healthcare Research and Quality, December (2012)
-
(2012)
Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness. Comparative effectiveness review no. 91. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 13-EHC009-EF. Rockville, MD
-
-
Sun, X.1
Patnode, C.2
Williams, C.3
Senger, C.4
Kapka, T.5
Whitlock, E.6
-
25
-
-
84885444012
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
-
COI: 1:STN:280:DC%2BC2c7gvVyksQ%3D%3D, PID: 24168254
-
Afdhal, N.H., Zeuzem, S., Schooley, R.T., Thomas, D.L., Ward, J.W., Litwin, A.H., Razavi, H., Castera, L., Poynard, T., Muir, A., et al.: The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J. Viral Hepat. 20, 745–760 (2013)
-
(2013)
J. Viral Hepat.
, vol.20
, pp. 745-760
-
-
Afdhal, N.H.1
Zeuzem, S.2
Schooley, R.T.3
Thomas, D.L.4
Ward, J.W.5
Litwin, A.H.6
Razavi, H.7
Castera, L.8
Poynard, T.9
Muir, A.10
-
26
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
COI: 1:CAS:528:DC%2BC3sXnsl2gsrY%3D, PID: 23607594
-
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R., et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878–1887 (2013)
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
Rodriguez-Torres, M.4
Hassanein, T.5
Gordon, S.C.6
Schultz, M.7
Davis, M.N.8
Kayali, Z.9
Reddy, K.R.10
-
27
-
-
84856159009
-
Preliminary study of two antiviral agents for hepatitis C genotype 1
-
COI: 1:CAS:528:DC%2BC38Xht1yltrw%3D, PID: 22256805
-
Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F., Wind-Rotolo, M., et al.: Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012)
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 216-224
-
-
Lok, A.S.1
Gardiner, D.F.2
Lawitz, E.3
Martorell, C.4
Everson, G.T.5
Ghalib, R.6
Reindollar, R.7
Rustgi, V.8
McPhee, F.9
Wind-Rotolo, M.10
-
28
-
-
84894065513
-
-
New York, NY: The New York Times Company
-
Pollack, A,: Hepatitis C, a silent killer, meets its match. New York Times, New York edn. New York, NY: The New York Times Company (2013)
-
(2013)
Hepatitis C, a silent killer, meets its match. New York Times, New York edn
-
-
Pollack, A.1
-
29
-
-
84876286638
-
Hepatitis C virus therapy update 2013
-
PID: 23563981
-
Casey, L.C., Lee, W.M.: Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 29, 243–249 (2013)
-
(2013)
Curr Opin Gastroenterol
, vol.29
, pp. 243-249
-
-
Casey, L.C.1
Lee, W.M.2
-
30
-
-
84899970077
-
The rapid evolution of treatment strategies for hepatitis C
-
COI: 1:CAS:528:DC%2BC2cXnslGitL4%3D, PID: 24732866
-
Muir, A.J.: The rapid evolution of treatment strategies for hepatitis C. Am. J. Gastroenterol. 109, 628–635 (2014)
-
(2014)
Am. J. Gastroenterol.
, vol.109
, pp. 628-635
-
-
Muir, A.J.1
-
31
-
-
84897441948
-
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C
-
PID: 24603445
-
Brogan, A.J., Talbird, S.E., Thompson, J.R., Miller, J.D., Rubin, J., Deniz, B.: Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS ONE 9, e90295 (2014)
-
(2014)
PLoS ONE
, vol.9
, pp. 90295
-
-
Brogan, A.J.1
Talbird, S.E.2
Thompson, J.R.3
Miller, J.D.4
Rubin, J.5
Deniz, B.6
-
32
-
-
84884549621
-
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons
-
Martin, N.K., Hickman, M., Miners, A., Hutchinson, S.J., Taylor, A., Vickerman, P.: Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3, e003153 (2013)
-
(2013)
BMJ Open
, vol.e003153
, pp. 3
-
-
Martin, N.K.1
Hickman, M.2
Miners, A.3
Hutchinson, S.J.4
Taylor, A.5
Vickerman, P.6
-
33
-
-
84155180685
-
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
-
PID: 21898506
-
Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M.: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55, 49–57 (2012)
-
(2012)
Hepatology
, vol.55
, pp. 49-57
-
-
Martin, N.K.1
Vickerman, P.2
Miners, A.3
Foster, G.R.4
Hutchinson, S.J.5
Goldberg, D.J.6
Hickman, M.7
-
34
-
-
84873427421
-
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
-
PID: 23329380
-
McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11, 53–63 (2013)
-
(2013)
Appl. Health Econ. Health Policy
, vol.11
, pp. 53-63
-
-
McEwan, P.1
Kim, R.2
Yuan, Y.3
-
35
-
-
67649839932
-
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines
-
PID: 19485429
-
Siebert, U., Sroczynski, G., Aidelsburger, P., Rossol, S., Wasem, J., Manns, M.P., McHutchison, J.G., Wong, J.B.: Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 27, 341–354 (2009)
-
(2009)
Pharmacoeconomics
, vol.27
, pp. 341-354
-
-
Siebert, U.1
Sroczynski, G.2
Aidelsburger, P.3
Rossol, S.4
Wasem, J.5
Manns, M.P.6
McHutchison, J.G.7
Wong, J.B.8
-
36
-
-
0037372609
-
German hepatitis CMG, international hepatitis interventional therapy G: cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
-
COI: 1:STN:280:DC%2BD3s%2FpsFyjtQ%3D%3D, PID: 12584228
-
Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B.M., Manns, M.P., McHutchison, J.G., Wong, J.B.: German hepatitis CMG, international hepatitis interventional therapy G: cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52, 425–432 (2003)
-
(2003)
Gut
, vol.52
, pp. 425-432
-
-
Siebert, U.1
Sroczynski, G.2
Rossol, S.3
Wasem, J.4
Ravens-Sieberer, U.5
Kurth, B.M.6
Manns, M.P.7
McHutchison, J.G.8
Wong, J.B.9
-
37
-
-
82955193770
-
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C
-
PID: 22152176
-
Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14, 1068–1077 (2011)
-
(2011)
Value Health
, vol.14
, pp. 1068-1077
-
-
Townsend, R.1
McEwan, P.2
Kim, R.3
Yuan, Y.4
-
38
-
-
33747189558
-
Preference-based measures: utility and quality-adjusted life years
-
Fayers P, Hays R, (eds), Oxford University Press, New York
-
Feeny, D.: Preference-based measures: utility and quality-adjusted life years. In: Fayers, P., Hays, R. (eds.) Assessing quality of life in clinical trials, 2nd edn, pp. 405–431. Oxford University Press, New York (2005)
-
(2005)
Assessing quality of life in clinical trials
, pp. 405-431
-
-
Feeny, D.1
-
39
-
-
84875734849
-
Health utility measurement
-
Glied S, Smith P, (eds), Oxford University Press, New York
-
Rowen, D., Brazier, J.: Health utility measurement. In: Glied, S., Smith, P. (eds.) The Oxford Handbook of Health Economics, pp. 788–813. Oxford University Press, New York (2011)
-
(2011)
The Oxford Handbook of Health Economics
, pp. 788-813
-
-
Rowen, D.1
Brazier, J.2
-
40
-
-
47249161145
-
Health-state utilities in liver disease: a systematic review
-
McLernon, D.J., Dillon, J., Donnan, P.T.: Health-state utilities in liver disease: a systematic review. Med. Decis. Mak. 28, 582–592 (2008)
-
(2008)
Med. Decis. Mak.
, vol.28
, pp. 582-592
-
-
McLernon, D.J.1
Dillon, J.2
Donnan, P.T.3
-
41
-
-
8844221170
-
Health values of patients with chronic hepatitis C infection
-
PID: 15557419
-
Sherman, K.E., Sherman, S.N., Chenier, T., Tsevat, J.: Health values of patients with chronic hepatitis C infection. Arch. Intern. Med. 164, 2377–2382 (2004)
-
(2004)
Arch. Intern. Med.
, vol.164
, pp. 2377-2382
-
-
Sherman, K.E.1
Sherman, S.N.2
Chenier, T.3
Tsevat, J.4
-
42
-
-
84891685662
-
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation
-
COI: 1:STN:280:DC%2BD28zjtVOhsQ%3D%3D
-
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., U. k. Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10, 1–113 (2006)
-
(2006)
Health Technol. Assess.
, vol.10
, pp. 1-113
-
-
Wright, M.1
Grieve, R.2
Roberts, J.3
Main, J.4
Thomas, H.C.5
-
43
-
-
0035120575
-
Assessment of utilities and health-related quality of life in patients with chronic liver disease
-
COI: 1:STN:280:DC%2BD3M7ot12lsg%3D%3D, PID: 11232711
-
Younossi, Z.M., Boparai, N., McCormick, M., Price, L.L., Guyatt, G.: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am. J. Gastroenterol. 96, 579–583 (2001)
-
(2001)
Am. J. Gastroenterol.
, vol.96
, pp. 579-583
-
-
Younossi, Z.M.1
Boparai, N.2
McCormick, M.3
Price, L.L.4
Guyatt, G.5
-
44
-
-
84155174944
-
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection
-
PID: 21679248
-
Hsu, P.C., Federico, C.A., Krajden, M., Yoshida, E.M., Bremner, K.E., Anderson, F.H., Weiss, A.A., Krahn, M.D.: Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J. Gastroenterol. Hepatol. 27, 149–157 (2012)
-
(2012)
J. Gastroenterol. Hepatol.
, vol.27
, pp. 149-157
-
-
Hsu, P.C.1
Federico, C.A.2
Krajden, M.3
Yoshida, E.M.4
Bremner, K.E.5
Anderson, F.H.6
Weiss, A.A.7
Krahn, M.D.8
-
45
-
-
85027938643
-
Impact of treatment attributes of peginterferon for hepatitis C on quality of life and treatment preference
-
Kerr, C., Lloyd, A., Ali, S., Gore, C., Tyas, D.A.: Impact of treatment attributes of peginterferon for hepatitis C on quality of life and treatment preference. Health Outcomes Res. Med. 3, e153–e167 (2012)
-
(2012)
Health Outcomes Res. Med.
, vol.3
, pp. 153-167
-
-
Kerr, C.1
Lloyd, A.2
Ali, S.3
Gore, C.4
Tyas, D.A.5
-
46
-
-
84873840448
-
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
-
COI: 1:CAS:528:DC%2BC3sXhvVymuro%3D, PID: 23159839
-
Cooper, C., Lester, R., Thorlund, K., Druyts, E., El Khoury, A.C., Yaya, S., Mills, E.J.: Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 106, 153–163 (2013)
-
(2013)
QJM
, vol.106
, pp. 153-163
-
-
Cooper, C.1
Lester, R.2
Thorlund, K.3
Druyts, E.4
El Khoury, A.C.5
Yaya, S.6
Mills, E.J.7
-
47
-
-
84876789373
-
Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population
-
COI: 1:CAS:528:DC%2BC3sXnvFahsL4%3D, PID: 23627926
-
Jin, Y.J., Lee, J.W., Lee, J.I., Park, S.H., Park, C.K., Kim, Y.S., Jeong, S.H., Kim, Y.S., Kim, J.H., Hwang, S.G., et al.: Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 13, 74 (2013)
-
(2013)
BMC Gastroenterol.
, vol.13
, pp. 74
-
-
Jin, Y.J.1
Lee, J.W.2
Lee, J.I.3
Park, S.H.4
Park, C.K.5
Kim, Y.S.6
Jeong, S.H.7
Kim, Y.S.8
Kim, J.H.9
Hwang, S.G.10
-
48
-
-
84947502298
-
EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. EuroQol Group Executive Office ed., Version 4.0 edition. Rotterdam, The Netherlands: EuroQol Group, pp
-
Rabin, R., Oemar, M., Oppe, M.: EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. EuroQol Group Executive Office ed., Version 4.0 edition. Rotterdam, The Netherlands: EuroQol Group, pp. 1–21 (2011)
-
(2011)
1–21
-
-
Rabin, R.1
Oemar, M.2
Oppe, M.3
-
49
-
-
3042545839
-
The Health Utilities Index (HUI): concepts, measurement properties and applications
-
PID: 14613568
-
Horsman, J., Furlong, W., Feeny, D., Torrance, G.: The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes 1, 54 (2003)
-
(2003)
Health Qual. Life Outcomes
, vol.1
, pp. 54
-
-
Horsman, J.1
Furlong, W.2
Feeny, D.3
Torrance, G.4
-
50
-
-
39449087063
-
Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens
-
COI: 1:CAS:528:DC%2BD1cXksFCju7w%3D, PID: 18282016
-
Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., Marchant, N.: Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 26, 217–234 (2008)
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 217-234
-
-
Chancellor, J.1
Aballea, S.2
Lawrence, A.3
Sheldon, R.4
Cure, S.5
Plun-Favreau, J.6
Marchant, N.7
-
51
-
-
79958062820
-
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
-
PID: 20224930
-
Boye, K.S., Matza, L.S., Walter, K.N., Van Brunt, K., Palsgrove, A.C., Tynan, A.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12, 219–230 (2011)
-
(2011)
Eur. J. Health Econ.
, vol.12
, pp. 219-230
-
-
Boye, K.S.1
Matza, L.S.2
Walter, K.N.3
Van Brunt, K.4
Palsgrove, A.C.5
Tynan, A.6
-
52
-
-
84859138459
-
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study
-
PID: 22472127
-
Osborne, R.H., Dalton, A., Hertel, J., Schrover, R., Smith, D.K.: Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual. Life Outcomes 10, 35 (2012)
-
(2012)
Health Qual. Life Outcomes
, vol.10
, pp. 35
-
-
Osborne, R.H.1
Dalton, A.2
Hertel, J.3
Schrover, R.4
Smith, D.K.5
-
53
-
-
84868459981
-
Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Support
-
COI: 1:STN:280:DC%2BC38vjs1Kmuw%3D%3D
-
Teuffel, O., Cheng, S., Ethier, M.C., Diorio, C., Martino, J., Mayo, C., Wing, R., Sung, L., Alibhai, S.M.: Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Support. Care Cancer 20, 2755–2764 (2012)
-
(2012)
Care Cancer
, vol.20
, pp. 2755-2764
-
-
Teuffel, O.1
Cheng, S.2
Ethier, M.C.3
Diorio, C.4
Martino, J.5
Mayo, C.6
Wing, R.7
Sung, L.8
Alibhai, S.M.9
-
54
-
-
0036016989
-
Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis
-
PID: 12180075
-
Feeny, D., Townsend, M., Furlong, W., Tomkins, D.J., Robinson, G.E., Torrance, G.W., Mohide, P.T., Wang, Q.: Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis. Genet Test 6, 39–46 (2002)
-
(2002)
Genet Test
, vol.6
, pp. 39-46
-
-
Feeny, D.1
Townsend, M.2
Furlong, W.3
Tomkins, D.J.4
Robinson, G.E.5
Torrance, G.W.6
Mohide, P.T.7
Wang, Q.8
-
55
-
-
79960006165
-
Utility scores and treatment preferences for clinical early-stage cervical cancer
-
PID: 21669383
-
Jewell, E.L., Smrtka, M., Broadwater, G., Valea, F., Davis, D.M., Nolte, K.C., Valea, R., Myers, E.R., Samsa, G., Havrilesky, L.J.: Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health 14, 582–586 (2011)
-
(2011)
Value Health
, vol.14
, pp. 582-586
-
-
Jewell, E.L.1
Smrtka, M.2
Broadwater, G.3
Valea, F.4
Davis, D.M.5
Nolte, K.C.6
Valea, R.7
Myers, E.R.8
Samsa, G.9
Havrilesky, L.J.10
-
56
-
-
80053043440
-
Patient preferences for different severities of and treatments for overactive bladder
-
PID: 22453849
-
Wu, J.M., Fulton, R.G., Amundsen, C.L., Knight, S.K., Kuppermann, M.: Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med. Reconstr. Surg. 17, 184–189 (2011)
-
(2011)
Female Pelvic Med. Reconstr. Surg.
, vol.17
, pp. 184-189
-
-
Wu, J.M.1
Fulton, R.G.2
Amundsen, C.L.3
Knight, S.K.4
Kuppermann, M.5
-
57
-
-
84947487069
-
-
Agency for Healthcare Research and Quality, November
-
Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E., Fu, R.: Treatment for Hepatitis C virus infection in adults. Comparative effectiveness review No. 76. (Prepared by Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 12(13)-EHC113-EF. Rockville, MD: Agency for Healthcare Research and Quality, November (2012)
-
(2012)
Treatment for Hepatitis C virus infection in adults. Comparative effectiveness review No. 76. (Prepared by Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.): AHRQ Publication No. 12(13)-EHC113-EF. Rockville, MD
-
-
Chou, R.1
Hartung, D.2
Rahman, B.3
Wasson, N.4
Cottrell, E.5
Fu, R.6
-
58
-
-
84881078908
-
Telaprevir: changing the standard of care of chronic hepatitis C
-
COI: 1:STN:280:DC%2BC3svptlSjsg%3D%3D, PID: 23525057
-
Rajani, A.K., Ravindra, B.K., Dkhar, S.A.: Telaprevir: changing the standard of care of chronic hepatitis C. J. Postgrad. Med. 59, 42–47 (2013)
-
(2013)
J. Postgrad. Med.
, vol.59
, pp. 42-47
-
-
Rajani, A.K.1
Ravindra, B.K.2
Dkhar, S.A.3
-
59
-
-
84876738261
-
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
-
PID: 23490868
-
Teixeira, R., Nascimento Yde, A., Crespo, D.: Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz. J. Infect. Dis. 17, 194–204 (2013)
-
(2013)
Braz. J. Infect. Dis.
, vol.17
, pp. 194-204
-
-
Teixeira, R.1
Nascimento Yde, A.2
Crespo, D.3
-
60
-
-
84865801719
-
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC38XhslOltL7L, PID: 22967776
-
Udina, M., Castellvi, P., Moreno-Espana, J., Navines, R., Valdes, M., Forns, X., Langohr, K., Sola, R., Vieta, E., Martin-Santos, R.: Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 73, 1128–1138 (2012)
-
(2012)
J. Clin. Psychiatry
, vol.73
, pp. 1128-1138
-
-
Udina, M.1
Castellvi, P.2
Moreno-Espana, J.3
Navines, R.4
Valdes, M.5
Forns, X.6
Langohr, K.7
Sola, R.8
Vieta, E.9
Martin-Santos, R.10
-
61
-
-
0030560819
-
Modelling valuations for health states: the effect of duration
-
COI: 1:STN:280:DyaK2s%2FntFKhsw%3D%3D, PID: 10162421
-
Dolan, P.: Modelling valuations for health states: the effect of duration. Health Policy 38, 189–203 (1996)
-
(1996)
Health Policy
, vol.38
, pp. 189-203
-
-
Dolan, P.1
-
62
-
-
0031279593
-
Modeling valuations for EuroQol health states
-
COI: 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D, PID: 9366889
-
Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)
-
(1997)
Med. Care
, vol.35
, pp. 1095-1108
-
-
Dolan, P.1
-
63
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
-
COI: 1:CAS:528:DC%2BC3sXlvFajtg%3D%3D, PID: 23281974
-
Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., Berrey, M.M.: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013)
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
Ding, X.4
Svarovskaia, E.5
Symonds, W.T.6
Hindes, R.G.7
Berrey, M.M.8
-
64
-
-
34347324128
-
Interferon-based treatment of chronic hepatitis C
-
COI: 1:CAS:528:DC%2BD2sXnsFKrurc%3D, PID: 17570576
-
Souvignet, C., Lejeune, O., Trepo, C.: Interferon-based treatment of chronic hepatitis C. Biochimie 89, 894–898 (2007)
-
(2007)
Biochimie
, vol.89
, pp. 894-898
-
-
Souvignet, C.1
Lejeune, O.2
Trepo, C.3
-
65
-
-
84947502299
-
-
Janssen-Cilag Pharmaceuticals: Summary of product characteristics: Incivo 375 mg film-coated tablets telaprevir. In Labelling, Package Leaflet. Latina, Italy: European Public Assessment Reports (EPAR)
-
Janssen-Cilag Pharmaceuticals: Summary of product characteristics: Incivo 375 mg film-coated tablets telaprevir. In Labelling, Package Leaflet. Latina, Italy: European Public Assessment Reports (EPAR)
-
-
-
-
66
-
-
84879664119
-
Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions
-
COI: 1:CAS:528:DC%2BC3sXhvVSmt7nN, PID: 23553423
-
Kiang, T.K., Wilby, K.J., Ensom, M.H.: Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin. Pharmacokinet. 52, 487–510 (2013)
-
(2013)
Clin. Pharmacokinet.
, vol.52
, pp. 487-510
-
-
Kiang, T.K.1
Wilby, K.J.2
Ensom, M.H.3
-
67
-
-
84868649787
-
Boceprevir in chronic hepatitis C infection: a perspective review
-
COI: 1:CAS:528:DC%2BC38Xptlyrur0%3D, PID: 23251772
-
Ascione, A.: Boceprevir in chronic hepatitis C infection: a perspective review. Ther. Adv. Chronic Dis. 3, 113–121 (2012)
-
(2012)
Ther. Adv. Chronic Dis.
, vol.3
, pp. 113-121
-
-
Ascione, A.1
-
68
-
-
84878799939
-
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
-
COI: 1:CAS:528:DC%2BC3sXhtF2qtL7F, PID: 23710734
-
Gordon, S.C., Yoshida, E.M., Lawitz, E.J., Bacon, B.R., Sulkowski, M.S., Davis, M., Poordad, F., Bronowicki, J.P., Esteban, R., Sniukiene, V., et al.: Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment. Pharmacol. Ther. 38, 16–27 (2013)
-
(2013)
Aliment. Pharmacol. Ther.
, vol.38
, pp. 16-27
-
-
Gordon, S.C.1
Yoshida, E.M.2
Lawitz, E.J.3
Bacon, B.R.4
Sulkowski, M.S.5
Davis, M.6
Poordad, F.7
Bronowicki, J.P.8
Esteban, R.9
Sniukiene, V.10
-
69
-
-
84947502300
-
Summary of product characteristics: victrelis 200 mg hard capsules boceprevir. In Labelling, Package Leaflet. Hertfordshire, UK: European Public Assessment Reports (EPAR)
-
Merck Sharp & Dohme: Summary of product characteristics: victrelis 200 mg hard capsules boceprevir. In Labelling, Package Leaflet. Hertfordshire, UK: European Public Assessment Reports (EPAR). Last updated on eMC 11 September 2014
-
(2014)
Last updated on eMC
, pp. 11
-
-
-
70
-
-
84872565980
-
Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review
-
PID: 23437439
-
Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E.B., Fu, R.: Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann. Intern. Med. 158, 114–123 (2013)
-
(2013)
Ann. Intern. Med.
, vol.158
, pp. 114-123
-
-
Chou, R.1
Hartung, D.2
Rahman, B.3
Wasson, N.4
Cottrell, E.B.5
Fu, R.6
-
71
-
-
84874798912
-
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
-
Koretz, R.L., Pleguezuelo, M., Arvaniti, V., Barrera Baena, P., Ciria, R., Gurusamy, K.S., Davidson, B.R., Burroughs, A.K.: Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Datab. Syst. Rev. 1, CD003617 (2013)
-
(2013)
Cochrane Datab. Syst. Rev.
, vol.1
, pp. 003617
-
-
Koretz, R.L.1
Pleguezuelo, M.2
Arvaniti, V.3
Barrera Baena, P.4
Ciria, R.5
Gurusamy, K.S.6
Davidson, B.R.7
Burroughs, A.K.8
-
72
-
-
84947502301
-
-
SP (Brinny) Company: Summary of product characteristics: IntronA 3 million IU/0.5 ml solution for injection or infusion interferon alfa-2b. In Labelling, Package Leaflet. County Cork, Ireland: European Public Assessment Reports (EPAR)
-
SP (Brinny) Company: Summary of product characteristics: IntronA 3 million IU/0.5 ml solution for injection or infusion interferon alfa-2b. In Labelling, Package Leaflet. County Cork, Ireland: European Public Assessment Reports (EPAR)
-
-
-
-
73
-
-
84947502302
-
-
Penn Pharmaceutical Services: Summary of product characteristics: Ribavirin Mylan 200 mg hard capsules In Labelling, Package Leaflet. Gwent County, UK: European Public Assessment Reports (EPAR)
-
Penn Pharmaceutical Services: Summary of product characteristics: Ribavirin Mylan 200 mg hard capsules In Labelling, Package Leaflet. Gwent County, UK: European Public Assessment Reports (EPAR)
-
-
-
-
74
-
-
51149089137
-
Valuing health states for use in cost-effectiveness analysis
-
PID: 18767897
-
Brazier, J.: Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 26, 769–779 (2008)
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 769-779
-
-
Brazier, J.1
-
76
-
-
84947502303
-
-
London, UK: National Institute for Health and Clinical Excellence
-
NICE (National Institute for Health and Clinical Excellence): Process and methods guides: guide to the methods of technology appraisal 2013. London, UK: National Institute for Health and Clinical Excellence (2013)
-
(2013)
Process and methods guides: guide to the methods of technology appraisal
, vol.2013
-
-
-
77
-
-
84947502304
-
Guidelines for preparing submissions to PBAC, Version 4.3.2
-
PBAC (Pharmaceutical Benefits Advisory Committee): Guidelines for preparing submissions to PBAC, Version 4.3.2. PBAC (2008)
-
(2008)
PBAC
-
-
-
78
-
-
0030102792
-
The time trade-off method: results from a general population study
-
COI: 1:STN:280:DyaK28zhtVWjtg%3D%3D, PID: 8733106
-
Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5, 141–154 (1996)
-
(1996)
Health Econ.
, vol.5
, pp. 141-154
-
-
Dolan, P.1
Gudex, C.2
Kind, P.3
Williams, A.4
-
79
-
-
12344257034
-
Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies
-
PID: 15386674
-
Arnesen, T., Trommald, M.: Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies. Health Econ. 14, 39–53 (2005)
-
(2005)
Health Econ.
, vol.14
, pp. 39-53
-
-
Arnesen, T.1
Trommald, M.2
-
80
-
-
49949098352
-
A community-based study of acne-related health preferences in adolescents
-
PID: 18711070
-
Chen, C.L., Kuppermann, M., Caughey, A.B., Zane, L.T.: A community-based study of acne-related health preferences in adolescents. Arch. Dermatol. 144, 988–994 (2008)
-
(2008)
Arch. Dermatol.
, vol.144
, pp. 988-994
-
-
Chen, C.L.1
Kuppermann, M.2
Caughey, A.B.3
Zane, L.T.4
-
81
-
-
84859979197
-
Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom
-
PID: 21988666
-
Guest, J.F., Naik, N., Sladkevicius, E., Coombs, J., Gray, E.J.: Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk. Lymphoma 53, 928–933 (2012)
-
(2012)
Leuk. Lymphoma
, vol.53
, pp. 928-933
-
-
Guest, J.F.1
Naik, N.2
Sladkevicius, E.3
Coombs, J.4
Gray, E.J.5
-
82
-
-
84898598799
-
Health state utilities for skeletal-related events secondary to bone metastases
-
PID: 23355121
-
Matza, L.S., Chung, K., Van Brunt, K., Brazier, J.E., Braun, A., Currie, B., Palsgrove, A., Davies, E., Body, J.J.: Health state utilities for skeletal-related events secondary to bone metastases. Eur. J. Health Econ. 15, 7–18 (2014)
-
(2014)
Eur. J. Health Econ.
, vol.15
, pp. 7-18
-
-
Matza, L.S.1
Chung, K.2
Van Brunt, K.3
Brazier, J.E.4
Braun, A.5
Currie, B.6
Palsgrove, A.7
Davies, E.8
Body, J.J.9
-
83
-
-
19344371117
-
Utility assessment among cataract surgery patients
-
PID: 15899457
-
Saw, S.M., Gazzard, G., Gomezperalta, C., Au Eong, K.G., Seah, S.: Utility assessment among cataract surgery patients. J. Cataract Refract. Surg. 31, 785–791 (2005)
-
(2005)
J. Cataract Refract. Surg.
, vol.31
, pp. 785-791
-
-
Saw, S.M.1
Gazzard, G.2
Gomezperalta, C.3
Au Eong, K.G.4
Seah, S.5
-
84
-
-
38349084979
-
Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study
-
COI: 1:STN:280:DC%2BD1c%2FmtFWlsQ%3D%3D, PID: 18070214
-
Schmitt, J., Meurer, M., Klon, M., Frick, K.D.: Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br. J. Dermatol. 158, 351–359 (2008)
-
(2008)
Br. J. Dermatol.
, vol.158
, pp. 351-359
-
-
Schmitt, J.1
Meurer, M.2
Klon, M.3
Frick, K.D.4
-
85
-
-
55549139518
-
Changing preferences for survival after hospitalization with advanced heart failure
-
PID: 19007689
-
Stevenson, L.W., Hellkamp, A.S., Leier, C.V., Sopko, G., Koelling, T., Warnica, J.W., Abraham, W.T., Kasper, E.K., Rogers, J.G., Califf, R.M., et al.: Changing preferences for survival after hospitalization with advanced heart failure. J. Am. Coll. Cardiol. 52, 1702–1708 (2008)
-
(2008)
J. Am. Coll. Cardiol.
, vol.52
, pp. 1702-1708
-
-
Stevenson, L.W.1
Hellkamp, A.S.2
Leier, C.V.3
Sopko, G.4
Koelling, T.5
Warnica, J.W.6
Abraham, W.T.7
Kasper, E.K.8
Rogers, J.G.9
Califf, R.M.10
-
86
-
-
34147177832
-
-
Oxford University Press, New York
-
Brazier, J.R., Ratcliffe, J., Salomon, J.A., Tsuchiya, A.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, New York (2007)
-
(2007)
Measuring and valuing health benefits for economic evaluation
-
-
Brazier, J.R.1
Ratcliffe, J.2
Salomon, J.A.3
Tsuchiya, A.4
-
87
-
-
84881162364
-
Incorporating process utility into quality adjusted life years: a systematic review of empirical studies
-
PID: 23771494
-
Brennan, V.K., Dixon, S.: Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics 31, 677–691 (2013)
-
(2013)
Pharmacoeconomics
, vol.31
, pp. 677-691
-
-
Brennan, V.K.1
Dixon, S.2
-
88
-
-
84884132445
-
Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
-
Matza, L.S., Cong, Z., Chung, K., Stopeck, A., Tonkin, K., Brown, J., Braun, A., Van Brunt, K., McDaniel, K.: Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adher. 7, 855–865 (2013)
-
(2013)
Patient Prefer Adher.
, vol.7
, pp. 855-865
-
-
Matza, L.S.1
Cong, Z.2
Chung, K.3
Stopeck, A.4
Tonkin, K.5
Brown, J.6
Braun, A.7
Van Brunt, K.8
McDaniel, K.9
-
89
-
-
0033840246
-
Development and testing of a utility measure for major, unipolar depression (McSad)
-
COI: 1:STN:280:DC%2BD3cvlsFahsA%3D%3D, PID: 10981211
-
Bennett, K.J., Torrance, G.W., Boyle, M.H., Guscott, R., Moran, L.A.: Development and testing of a utility measure for major, unipolar depression (McSad). Qual. Life Res. 9, 109–120 (2000)
-
(2000)
Qual. Life Res.
, vol.9
, pp. 109-120
-
-
Bennett, K.J.1
Torrance, G.W.2
Boyle, M.H.3
Guscott, R.4
Moran, L.A.5
-
90
-
-
0031938365
-
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications
-
COI: 1:STN:280:DyaK1c7lsV2rtQ%3D%3D, PID: 9495599
-
Revicki, D.A., Wood, M.: Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J. Affect. Disord. 48, 25–36 (1998)
-
(1998)
J. Affect. Disord.
, vol.48
, pp. 25-36
-
-
Revicki, D.A.1
Wood, M.2
-
91
-
-
4243147176
-
Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder
-
PID: 15128456
-
Sapin, C., Fantino, B., Nowicki, M.L., Kind, P.: Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2, 20 (2004)
-
(2004)
Health Qual. Life Outcomes
, vol.2
, pp. 20
-
-
Sapin, C.1
Fantino, B.2
Nowicki, M.L.3
Kind, P.4
-
92
-
-
33947591945
-
Health-related quality of life measured with EQ-5D in patients treated for depression in primary care
-
PID: 17391424
-
Sobocki, P., Ekman, M., Agren, H., Krakau, I., Runeson, B., Martensson, B., Jonsson, B.: Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 10, 153–160 (2007)
-
(2007)
Value Health
, vol.10
, pp. 153-160
-
-
Sobocki, P.1
Ekman, M.2
Agren, H.3
Krakau, I.4
Runeson, B.5
Martensson, B.6
Jonsson, B.7
-
93
-
-
0034917145
-
Introducing economic and quality of life measurements into clinical studies
-
COI: 1:STN:280:DC%2BD3MvksFWqsA%3D%3D, PID: 11491193
-
Drummond, M.: Introducing economic and quality of life measurements into clinical studies. Ann. Med. 33, 344–349 (2001)
-
(2001)
Ann. Med.
, vol.33
, pp. 344-349
-
-
Drummond, M.1
-
94
-
-
20144374806
-
The minimally clinically important difference in generic utility-based measures
-
PID: 17136968
-
Kaplan, R.M.: The minimally clinically important difference in generic utility-based measures. COPD 2, 91–97 (2005)
-
(2005)
COPD
, vol.2
, pp. 91-97
-
-
Kaplan, R.M.1
-
95
-
-
77950282183
-
Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments
-
PID: 20355266
-
Luo, N., Johnson, J., Coons, S.J.: Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med. Care 48, 365–371 (2010)
-
(2010)
Med. Care
, vol.48
, pp. 365-371
-
-
Luo, N.1
Johnson, J.2
Coons, S.J.3
-
96
-
-
12344320344
-
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis
-
PID: 15652688
-
Marra, C.A., Woolcott, J.C., Kopec, J.A., Shojania, K., Offer, R., Brazier, J.E., Esdaile, J.M., Anis, A.H.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)
-
(2005)
Soc. Sci. Med.
, vol.60
, pp. 1571-1582
-
-
Marra, C.A.1
Woolcott, J.C.2
Kopec, J.A.3
Shojania, K.4
Offer, R.5
Brazier, J.E.6
Esdaile, J.M.7
Anis, A.H.8
-
97
-
-
39749097822
-
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
-
PID: 18154669
-
Pickard, A.S., Neary, M.P., Cella, D.: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5, 70 (2007)
-
(2007)
Health Qual Life Outcomes
, vol.5
, pp. 70
-
-
Pickard, A.S.1
Neary, M.P.2
Cella, D.3
-
98
-
-
0003662748
-
Guide to design and development of health-state utility instrumentation. Hamilton, ON: McMaster University
-
Furlong, W., Feeny, D.H., Torrance, G.W., et al.: Guide to design and development of health-state utility instrumentation. Hamilton, ON: McMaster University, Report No. 90-99 (1990)
-
(1990)
Report No
, pp. 90-99
-
-
Furlong, W.1
Feeny, D.H.2
Torrance, G.W.3
-
99
-
-
84863061002
-
Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury
-
PID: 22289233
-
Lin, M.R., Yu, W.Y., Wang, S.C.: Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch. Phys. Med. Rehabil. 93, 245–252 (2012)
-
(2012)
Arch. Phys. Med. Rehabil.
, vol.93
, pp. 245-252
-
-
Lin, M.R.1
Yu, W.Y.2
Wang, S.C.3
-
100
-
-
84947502305
-
-
Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., McDaniel, K., Jordan, J., Devine, K., Davies, E.: The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In ISPOR 15th Annual European Congress; November 3–7, 2012, Berlin, Germany (2012)
-
Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., McDaniel, K., Jordan, J., Devine, K., Davies, E.: The time horizon matters: exploratory results varying the time horizon in time trade-off and standard gamble utility elicitation. In ISPOR 15th Annual European Congress; November 3–7, 2012, Berlin, Germany (2012)
-
-
-
-
101
-
-
0028979652
-
The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off
-
COI: 1:STN:280:DyaK28%2FhtVSisg%3D%3D, PID: 7561982
-
Stiggelbout, A.M., Kiebert, G.M., Kievit, J., Leer, J.W., Habbema, J.D., De Haes, J.C.: The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J. Clin. Epidemiol. 48, 1207–1214 (1995)
-
(1995)
J. Clin. Epidemiol.
, vol.48
, pp. 1207-1214
-
-
Stiggelbout, A.M.1
Kiebert, G.M.2
Kievit, J.3
Leer, J.W.4
Habbema, J.D.5
De Haes, J.C.6
-
102
-
-
67149139335
-
The influence of subjective life expectancy on health state valuations using a 10 year TTO
-
PID: 18702082
-
van Nooten, F.E., Koolman, X., Brouwer, W.B.: The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ. 18, 549–558 (2009)
-
(2009)
Health Econ.
, vol.18
, pp. 549-558
-
-
van Nooten, F.E.1
Koolman, X.2
Brouwer, W.B.3
-
103
-
-
84900360613
-
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO
-
van Nooten, F.E., Koolman, X., Busschbach, J.J., Brouwer, W.B.: Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO. Qual. Life Res. 23, 377–384 (2013)
-
(2013)
Qual. Life Res
, vol.23
, pp. 377-384
-
-
van Nooten, F.E.1
Koolman, X.2
Busschbach, J.J.3
Brouwer, W.B.4
-
104
-
-
0027450184
-
Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer
-
COI: 1:STN:280:DyaK3s7mtlyiuw%3D%3D, PID: 8433117
-
Gerard, K., Dobson, M., Hall, J.: Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J. Clin. Epidemiol. 46, 77–84 (1993)
-
(1993)
J. Clin. Epidemiol.
, vol.46
, pp. 77-84
-
-
Gerard, K.1
Dobson, M.2
Hall, J.3
-
105
-
-
84856607845
-
It’s all in the name, or is it? The impact of labeling on health state values
-
Rowen, D., Brazier, J., Tsuchiya, A., Young, T., Ibbotson, R.: It’s all in the name, or is it? The impact of labeling on health state values. Med. Decis. Mak. 32, 31–40 (2012)
-
(2012)
Med. Decis. Mak.
, vol.32
, pp. 31-40
-
-
Rowen, D.1
Brazier, J.2
Tsuchiya, A.3
Young, T.4
Ibbotson, R.5
-
106
-
-
0018155086
-
The utility of different health states as perceived by the general public
-
COI: 1:STN:280:DyaE1M%2FovVyltw%3D%3D, PID: 730825
-
Sackett, D.L., Torrance, G.W.: The utility of different health states as perceived by the general public. J. Chronic. Dis. 31, 697–704 (1978)
-
(1978)
J. Chronic. Dis.
, vol.31
, pp. 697-704
-
-
Sackett, D.L.1
Torrance, G.W.2
|